Saturday, 3 October 2026European Markets

IBERSOL,SGPS And 3 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Loading stream...

(VIANEWS) - IBERSOL,SGPS (IBS.LS), SALMAR (SALM.OL), PROTECTOR FORSIKRG (PROT.OL) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. IBERSOL,SGPS (IBS.LS)

500.5% sales growth and 35.54% return on equity

Ibersol, S.G.P.S., S.A., through its subsidiaries, operates a network of restaurants in Portugal, Spain, and Angola. The company operates restaurants under various brands, including Pizza Hut, Pasta Caffé, Pans & Company, Ribs, FresCo, SantaMaria, Kentucky Fried Chicken, Burger King, O' Kilo, Quiosques, Pizza Móvil, Miit, Taco Bell, Sol, Silva Carvalho Catering e Palace Catering, Travel, coffee counters, and other concessions contract. The company was founded in 1989 and is headquartered in Porto, Portugal. Ibersol, S.G.P.S., S.A. is a subsidiary of ATPS - SGPS, S.A.

Earnings Per Share

As for profitability, IBERSOL,SGPS has a trailing twelve months EPS of €-0.92.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 35.54%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Jun 17, 2022, the estimated forward annual dividend rate is 0.14 and the estimated forward annual dividend yield is 2.15%.

Moving Average

IBERSOL,SGPS's value is way higher than its 50-day moving average of €5.94 and way higher than its 200-day moving average of €5.91.

Sales Growth

IBERSOL,SGPS's sales growth is negative 28.8% for the current quarter and 500.5% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

IBERSOL,SGPS's EBITDA is 102.67.

2. SALMAR (SALM.OL)

45.8% sales growth and 18.21% return on equity

SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, the United States, Canada, Norway, rest of Europe, and internationally. It is involved in the broodfish, lumpfish, and smolt production activities; and marine-phase farming, harvesting, packaging, processing, and selling farmed salmon. The company sells its products to importers/exporters, processing companies, and retail chains through in-house sales force and/or through partners. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.

Earnings Per Share

As for profitability, SALMAR has a trailing twelve months EPS of kr17.49.

PE Ratio

SALMAR has a trailing twelve months price to earnings ratio of 23.89. Meaning, the purchaser of the share is investing kr23.89 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.21%.

Moving Average

SALMAR's worth is under its 50-day moving average of kr420.83 and way below its 200-day moving average of kr504.50.

Earnings Before Interest, Taxes, Depreciation, and Amortization

SALMAR's EBITDA is 43.28.

3. PROTECTOR FORSIKRG (PROT.OL)

16.2% sales growth and 24.01% return on equity

Protector Forsikring ASA, a general insurance company, provides various insurance products to the commercial and public sectors, and the affinity insurance markets in Norway, Denmark, Sweden, the United Kingdom, and Finland. It operates in two segments, Commercial Lines of Business and Public Lines of Business. The company offers personal, motor, property, liability, and change of ownership insurance. It sells its products to non-marine industries through insurance brokers. The company was founded in 2003 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PROTECTOR FORSIKRG has a trailing twelve months EPS of kr23.84.

PE Ratio

PROTECTOR FORSIKRG has a trailing twelve months price to earnings ratio of 6.28. Meaning, the purchaser of the share is investing kr6.28 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 24.01%.

Growth Estimates Quarters

The company's growth estimates for the present quarter and the next is 984% and 473%, respectively.

Volume

Today's last reported volume for PROTECTOR FORSIKRG is 63848 which is 1.26% below its average volume of 64668.

4. ROBERTET (RBT.PA)

14.1% sales growth and 14.34% return on equity

Robertet SA produces and sells perfumes, aromas, and natural products. The company operates in three segments: Raw materials, Fragrances, and Flavors. It also produces organic essential oils and active ingredients. The company operates in North America, Europe, the Asia Pacific, South America, Caribbean, Africa, and the Middle East. Robertet SA was founded in 1850 and is headquartered in Grasse, France.

Earnings Per Share

As for profitability, ROBERTET has a trailing twelve months EPS of €21.87.

PE Ratio

ROBERTET has a trailing twelve months price to earnings ratio of 40.05. Meaning, the purchaser of the share is investing €40.05 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.34%.

Volume

Today's last reported volume for ROBERTET is 24 which is 92.56% below its average volume of 323.

Sales Growth

ROBERTET's sales growth is 14.1% for the present quarter and 14.1% for the next.

Yearly Top and Bottom Value

ROBERTET's stock is valued at €876.00 at 01:20 EST, under its 52-week high of €959.00 and way above its 52-week low of €772.00.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Jun 29, 2022, the estimated forward annual dividend rate is 8 and the estimated forward annual dividend yield is 0.88%.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com